The authors would like to thank all the investigators who participated in this clinical trial as well as study nurses and other staff members. They would also like to acknowledge the parents and children who participated in the study. We thank Jennifer Coward, who provided medical writing services, and Catherine Arnaudeau-Bégard for publication coordination. GlaxoSmithKline Biologicals took in charge all the costs associated with the development and the publishing of the present manuscript.
Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months–2 years or 2–6 years primed with measles-mumps-rubella (MMR) vaccine / Y., Gillet; G. C., Steri; U., Behre; J. P., Arsène; X., Lanse; K., Helm; Esposito, Susanna Maria Roberta; N., Meister; M. G., Desole; M., Douha; P., Willems. - In: VACCINE. - ISSN 0264-410X. - 27:3(2009), pp. 446-453. [10.1016/j.vaccine.2008.10.064]
Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months–2 years or 2–6 years primed with measles-mumps-rubella (MMR) vaccine
Esposito, Susanna Maria Roberta;
2009-01-01
Abstract
The authors would like to thank all the investigators who participated in this clinical trial as well as study nurses and other staff members. They would also like to acknowledge the parents and children who participated in the study. We thank Jennifer Coward, who provided medical writing services, and Catherine Arnaudeau-Bégard for publication coordination. GlaxoSmithKline Biologicals took in charge all the costs associated with the development and the publishing of the present manuscript.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
